News - Page 183 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

Post published:May 19, 2021
Post category:Press Release

Read more about the article The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Post published:May 18, 2021
Post category:Press Release

Read more about the article Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

Post published:May 18, 2021
Post category:Press Release

Read more about the article Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Post published:May 18, 2021
Post category:Press Release

Read more about the article Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

Post published:May 18, 2021
Post category:Press Release

Read more about the article More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey

More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey

Post published:May 18, 2021
Post category:Press Release

Read more about the article Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

Post published:May 17, 2021
Post category:Press Release

Read more about the article Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

Post published:May 17, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Post published:May 17, 2021
Post category:Press Release

Read more about the article PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Post published:May 17, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.